What is Fosamax?
Fosamax (Alendronate) is a type of drug known as a bisphosphonate. It is designed to strengthen bone in people suffering from osteoporosis. However, the drug can have the reverse effect and weaken bones instead: leading to a serious bone disease called osteonecrosis or "dead jaw" a disease in which a patient's jaw bone rots and dies resulting in, amongst other conditions, a loosening of teeth, severe infections, swelling and increased risk of femur bone fractures.
Merck & Co., the manufacturer of Fosamax, marketed Fosamax aggressively and today has more than $3 billion in annual sales. Doctors wrote 22.4 million prescriptions for Fosamax in the U.S. last year.
Recent breaking news in the Wall Street Journal reported claims that Merck, the manufacturer of Fosamax, sold and heavily marketed the drug as safe, despite knowing about its dangerous side effects.
Additionally, that it failed to timely change its label to reflect the risk of their product
Our Law firm has extensive experience in representing victims of unsafe pharmaceutical products. Our firm filed the first suit against Merck & Co., Inc.'s in Superior Court of the State of New Jersey, Atlantic County, on behalf of our client who is a retired 77-year old Married Man from Smithtown, New York, who was recently diagnosed with Osteonecrosis of the jaw (ONJ).
If you suspect that you or your loved one has suffered any serious side effects from Fosamax or any other pharmaceutical products please don't hesitate to contact us.
If you or a loved one has suffered any serious side effects from Fosamax, contact us for a free consultation. You may very well be entitled to compensation for your injuries.
F.D.A. to Review Safety of Popular Bone Drugs
Two advisory panels of the Food and Drug Administration will consider on Friday whether to recommend requiring women who use popular bone drugs like Fosamax to take “drug holidays” because of rising concerns about rare side effects with long-term use, according to people involved in the review.
The panels and F.D.A. staff members are also expected to conduct a comprehensive safety review of the medical evidence to date, after 16 years of growing use of the drugs, to determine whether they have proved to be safe and effective in use longer than three to five years. The recommendation could affect many of the estimated four million women in the United States who take the drugs, called bisphosphonates. Bisphosphonates inhibit a bone renewal process called resorption, adding bone mass, but possibly causing brittleness as well.
Fosamax and Femur Fractures
Top 9 Health Stories of 2010 - ABC News
Bisphosphonates are commonly prescribed to prevent osteoporosis and make bones stronger. But an ABC News investigation found mounting evidence that for some women, taking the popular osteoporosis drug Fosamax or its generic alendronate for more than five years could cause spontaneous thigh-bone fractures.
The U.S. Food and Drug Administration announced in March that it will look into whether a link exists between the long-term use of the osteoporosis drugs and femur fractures after ABC News investigated the possible connection.
"We are seeing people just walking, walking down the steps, patients who are doing low-energy exercise," said Dr. Kenneth Egol, professor of orthopedic surgery at NYU Langone Medical Center. "Very unusual, the femur is one of the strongest bones in the body."
Egol said X-rays of some of his patients look more like an injury endured by a car accident than an otherwise minimal fall.
Many studies suggest an overall benefit from taking the medication for women who are at risk for osteoperosis. Indeed, bisphosphonates can help prevent hip and spine fractures, which for many women may lead to death.
Although bisphosphonates are generally recommended for postmenopausal women, research does not indicate how long women should be on the drug. Many doctors now recommend a five-year limit.
Merck Loses $8 Million Verdict in Trial Over Fosamax
Merck & Co. lost the second trial to reach a verdict over claims its osteoporosis drug Fosamax causes so-called jaw death. A jury in New York ruled against Merck today in the case of Shirley Boles, 72, of Fort Walton Beach, Florida, awarding $3 million more than the $5 million her lawyer had asked for. Boles claimed she developed osteonecrosis of the jaw, or ONJ, from taking Fosamax. The first Fosamax case resulted in a Merck victory in may.
The Sanders Firm is Ready and Eager for The First Fosamax Trial
The Atlantic County Superior Court of New Jersey has set the first jury trial (Docket No. ATL-L-3644-08) concerning Fosamax for January 24, 2011, with the case meant to serve as a “bell-weather” for thousands of others pending before the court. The plaintiff is an osteoporosis sufferer that used the drug for approximately 4 years before she developed severe osteonecrosis of the jaw, a debilitating condition suffered by thousands of other women who used Fosamax. Osteonecrosis of the jaw is the permanent death of living bone tissue that requires extensive treatment to correct and causes considerable pain and disfigurement.
They Call It "Dead Jaw"
Every month Marc Grossman's firm hears from more American women whose lives have become a living hell because they had oral surgery while taking Fosamax. In a few months' time, Grossman will go head to head with pharmaceutical giant Merck in hopes of getting justice for the victims and ultimately forcing Merck to pull the drug off the market.
"The Fosamax case is far more important than most drug litigations because Fosamax is still being sold and still causing extraordinary harm to innocent women," says Grossman, a partner in the Sanders Firm on Long Island. "I have met with over 50 Fosamax victims and many of their doctors. These women are suffering dearly."
FDA to Investigate Fosamax and link to Bone Fractures
Recent ABC News Investigation reports raised questions whether a link exists between the long-term use of certain osteoporosis drugs like Fosamax, Actonel, Boniva and Reclast, and particular type of leg fractures that may be caused from weakened bones.
"Recent news reports have raised the question about whether there is an increased risk of this type of fracture in patients with osteoporosis using these medications," the FDA said March 10th, in its drug safety communication.
First Case Brought In New Jersey by The Sanders Firm
Sanders Viener Grossman, LLP files first suit against Merck & Co., Inc.'s (NYSE: MRK) in Superior Court of the State of New Jersey, Atlantic County, on behalf of a retired 77-year old Married Man from Smithtown, New York, who was recently diagnosed with Osteonecrosis of the jaw (ONJ).
Merck Wins First Fosamax 'Jaw Death' State-Court Trial
Merck & Co. won the first of hundreds of state-court lawsuits in which its Fosamax osteoporosis drug blamed for causing so-called jaw death.
Rosenberg's attorney, Marc Grossman plans to appeal the case, saying Merck "can't keep getting away with hiding the risks of their drugs."